Skip to main content

Stifel Nicolaus Keeps Their Buy Rating on AbCellera Biologics (ABCL)

Tipranks - Tipranks - Sat Nov 8, 2025

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on AbCellera Biologics, with a price target of $7.00.

Meet Your ETF AI Analyst

According to TipRanks, Willey is a 4-star analyst with an average return of 6.8% and a 43.83% success rate. Willey covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Insmed, and Zymeworks.

In addition to Stifel Nicolaus, AbCellera Biologics also received a Buy from TD Cowen’s Brendan Smith in a report issued today. However, on the same day, Leerink Partners downgraded AbCellera Biologics (NASDAQ: ABCL) to a Hold.

See today’s best-performing stocks on TipRanks >>

Based on AbCellera Biologics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $17.08 million and a GAAP net loss of $34.73 million. In comparison, last year the company earned a revenue of $7.32 million and had a GAAP net loss of $36.93 million

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).